Johnson & Johnson to license novel oral atopic dermatitis candidate

 

The Company is licensing a STAT6 program from Kaken Pharmaceutical that targets a clinically relevant pathway in atopic dermatitis as well as other autoimmune and allergic diseases

The agreement bolsters Johnson & Johnson’s commitment to addressing disease-relevant pathways across patient types through novel mechanisms and modalities to transform the treatment of atopic dermatitis as well as other autoimmune and allergic diseases

https://www.jnj.com/media-center/press-releases/johnson-johnson-to-license-novel-oral-assets-further-strengthening-commitment-to-atopic-dermatitis